EPHB4 and breast carcinoma: In preclinical breast cancer models, the IGF1/IGF1R/Akt axis sustained mRNA expression of EphB4, thereby promoting cell proliferation and migration responses, which were sentitive to the PI3K inhibitor LY294002 [209].